TA
ABBV icon

TFG Advisers’s AbbVie ABBV Stock Holding History

TFG Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$3.88M Sell
20,918
-34
-0.2% -$6.32K 1.33% 13
2025
Q1 		$4.39M Buy
20,952
+122
+0.6% +$23.7K 1.59% 10
2024
Q4 		$3.7M Buy
20,830
+111
+0.5% +$20.4K 1.33% 13
2024
Q3 		$4.09M Sell
20,719
-207
-1% -$38.6K 1.47% 10
2024
Q2 		$3.59M Buy
20,926
+82
+0.4% +$13.6K 1.39% 11
2024
Q1 		$3.8M Buy
20,844
+289
+1% +$49.8K 1.49% 11
2023
Q4 		$3.19M Buy
20,555
+487
+2% +$71K 1.34% 15
2023
Q3 		$2.99M Buy
20,068
+707
+4% +$104K 1.41% 15
2023
Q2 		$2.61M Buy
19,361
+528
+3% +$77.4K 1.19% 20
2023
Q1 		$3M Buy
18,833
+1,096
+6% +$168K 1.45% 15
2022
Q4 		$2.87M Buy
17,737
+1,013
+6% +$155K 1.47% 17
2022
Q3 		$2.25M Buy
16,724
+1,435
+9% +$206K 1.25% 20
2022
Q2 		$2.34M Buy
15,289
+670
+5% +$102K 1.25% 19
2022
Q1 		$2.37M Buy
14,619
+249
+2% +$36.2K 1.09% 22
2021
Q4 		$1.95M Buy
14,370
+361
+3% +$42.6K 0.85% 33
2021
Q3 		$1.51M Buy
14,009
+103
+0.7% +$11.8K 0.73% 37
2021
Q2 		$1.57M Sell
13,906
-124
-0.9% -$14K 0.76% 38
2021
Q1 		$1.52M Buy
14,030
+386
+3% +$41.3K 0.78% 39
2020
Q4 		$1.46M Buy
13,644
+556
+4% +$53.4K 0.77% 41
2020
Q3 		$1.15M Buy
13,088
+1,158
+10% +$109K 0.66% 45
2020
Q2 		$1.17M Buy
11,930
+891
+8% +$78.4K 0.76% 41
2020
Q1 		$841K Buy
11,039
+368
+3% +$31.3K 0.67% 51
2019
Q4 		$944K Buy
10,671
+147
+1% +$12.2K 0.53% 60
2019
Q3 		$796K Sell
10,524
-63
-0.6% -$4.32K 0.53% 65
2019
Q2 		$769K Sell
10,587
-77
-0.7% -$6.05K 0.52% 68
2019
Q1 		$859K Buy
10,664
+987
+10% +$80.7K 0.62% 62
2018
Q4 		$892K Buy
+9,677
New +$851K 0.75% 47

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

TFG Advisers's ABBV Position: Q2 2025 in Review

TFG Advisers reduced its AbbVie (ABBV) stake by 0.16% in Q2 2025, selling an estimated $6.32K and leaving 20,918 shares worth $3.88M. The position accounts for 1.33% of the portfolio, ranked #13.

TFG Advisers first reported a position in ABBV in Q4 2018 and has held it in 27 quarters since. The position peaked at $4.39M in Q1 2025. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • TFG Advisers held 20,918 shares of AbbVie worth $3.88M as of Q2 2025.
  • TFG Advisers sold 34 AbbVie shares in Q2 2025, an estimated $6.32K.
  • AbbVie made up 1.33% of TFG Advisers's portfolio in Q2 2025, its #13 holding.
  • TFG Advisers first reported a position in AbbVie in Q4 2018 and has held it in 27 quarters since.
  • TFG Advisers's AbbVie position peaked at $4.39M in Q1 2025.
  • 3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on TFG Advisers's 13F filing for Q2 2025, filed 21 Jul 2025.